secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001655759-25-000103
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports preclinical data for PROTAC BCL6 degrader ARV-393 at EHA 2025
-----------------------------------------------------------------------------

- Single-agent ARV-393 reduced tumor burden in peripheral blood, bone marrow, and spleen in nTFHL-AI PDX model from a post-chemo relapsed patient.
- ARV-393 monotherapy achieved ≥95% tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL).
- Combinations with 5 small molecule inhibitors (tazemetostat, palbociclib, everolimus, acalabrutinib, venetoclax) enhanced TGI; regressions seen with 4 of 5.
- Phase 1 study (NCT06393738) enrolling relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL and AITL.
- Data suggest broad utility across NHL subtypes and support chemotherapy-free combination strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/0001655759-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/arvn-20250613.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer